Vischer advises Pureos on NovaGo financing round
Vischer advised Pureos Bioventures in connection with its role of co-lead investor on NovaGo Therapeutics’ Series B financing round of USD 30 million.
NovaGo Therapeutics is a clinical-stage biotechnology company developing anti-Nogo-A biologics for diseases of the central nervous system.
The round was co-led by Pureos Bioventures and Neurimmune, with participation from existing and new investors.
Legal team
The Vischer team advising Pureos Bioventures was led by Matthias Staehelin, partner in the corporate/M&A practice, together with Tobias F. Rohner, partner in the tax practice, and Natacha Tang, associate in the corporate/M&A practice.
